Zilico recognised in 2017 Global Digital Health 100
Friday 12th January 2018
Global Digital Health 100 is one of the HealthTech industries foremost technology award programmes, celebrating innovation and entrepreneurship. It supports health technology companies that are demonstrating the greatest potential to change the way healthcare is delivered.
Zilico's product portfolio is centred on its patented Electrical Impedance Spectroscopy (EIS) technology, which has applicability across a wide range of neoplastic conditions. ZedScan™, Zilico’s first product to market is a portable, handheld device, which uses real-time EIS technology to increase the detection of high grade cervical intraepithelial neoplasia (HG-CIN) and cancer of the cervix, removing subjectivity and increasing diagnostic accuracy.
To be included in the 2017 Global Digital Health 100, the judging criteria analysed 10 different quantitative and qualitative evaluation metrics including: disruptive impact; proof of concept; technology innovation; social value; effectiveness; execution of strategy; and, industry integration.
“We are delighted to be included in Global Digital Health 100, which is the international benchmark of innovation in the healthcare technology industry,” enthuses Sameer Kothari, CEO of Zilico. “As well as cervical cancer application, our patented diagnostic EIS technology is being developed across a wide range of other diagnostic areas such as oral, anal and vulval cancers. This award recognises the impact and importance that our technology has in improving diagnostic outcomes across different global healthcare settings – from mature to emerging.”News